Ortho-McNeil Pharmaceutical

From WikiMD's WELLNESSPEDIA


Ortho-McNeil Pharmaceutical was a pharmaceutical company that operated as a subsidiary of Johnson & Johnson. It was known for developing and marketing a range of prescription medications, particularly in the fields of neurology, psychiatry, and women's health.

History[edit]

Ortho-McNeil Pharmaceutical was formed through the merger of two companies: Ortho Pharmaceutical and McNeil Pharmaceutical. Ortho Pharmaceutical was originally founded in 1931 and was known for its contributions to the field of contraception and women's health. McNeil Pharmaceutical, on the other hand, was established in 1879 and became well-known for its development of Tylenol, a widely used analgesic.

The merger of these two companies allowed Ortho-McNeil to leverage the strengths of both entities, expanding its product offerings and research capabilities. The company became a significant player in the pharmaceutical industry, particularly in the United States.

Products[edit]

Ortho-McNeil Pharmaceutical developed and marketed a variety of prescription medications. Some of the notable products included:

Research and Development[edit]

The company invested heavily in research and development to bring new and innovative treatments to market. Ortho-McNeil's R&D efforts were focused on areas such as central nervous system disorders, infectious diseases, and women's health.

Merger and Transition[edit]

In 2008, Ortho-McNeil Pharmaceutical was merged with Janssen Pharmaceutica, another subsidiary of Johnson & Johnson, to form Ortho-McNeil-Janssen Pharmaceuticals. This merger was part of a strategic move to consolidate Johnson & Johnson's pharmaceutical operations and streamline its product offerings.

Related pages[edit]


Johnson & Johnson
Product
brands
Companies
People
Executives and scientists
* Joaquin Duato (Chairman and CEO)
Board of directors
Founders
Former executives,
board members,
and scientists
Former
subsidiaries

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Ortho-McNeil_Pharmaceutical&oldid=6629788"